ACP 103,
ACP-103,
ACP103,
bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate,
N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide,
Nuplazid,
Pimavanserin,
pimavanserin tartrate,
urea, n-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1),
Pimavanserin,
706779-91-1,
1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea,
ACP-103,
UNII-JZ963P0DIK,
JZ963P0DIK,
1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea,
N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide,
J-503297,
Pimavanserin [INN],
Pimanavserin,
AC-5273,
Pimavanserin(ACP-103),
SCHEMBL675165,
I14-1981,
Nuplazid (proposed trade name),
GTPL8423,
CHEMBL2111101,
C25H34FN3O2,
CTK6A8888,
CHEBI:133017,
RKEWSXXUOLRFBX-UHFFFAOYSA-N,
BDBM139370,
BCP11618,
EBD38047,
AN-672,
MFCD09953792,
ZINC16159083,
AKOS015902593,
API0003848,
CS-3378,
DB05316,
ME-0240,
RP07134,
SB16963,
NCGC00390656-01,
HY-14557,
SC-20247,
B8019,
FT-0653701,
Y0393,
KS-00000647,
A14434,
779P911,
A836958,
1-[(4-fluorophenyl)methyl]-3-[(4-isobutoxyphenyl)methyl]-1-(1-methyl-4-piperidyl)urea,
1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidinyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea,
N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea,
Nuplazid,
Pimavanserin tartrate,
D0J8JP,
ACP 103,
CS-T-39971,
CID10071196,
ST51054136,
1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea,
706782-28-7,